Osage University Partners

AssetWatch specializes in proactive predictive maintenance solutions. It offers a rapidly deployable remote condition monitoring service featuring wireless sensors, communication hubs, advanced software, and expert analysis. The company combines predictive analytics with expert insights to provide actionable recommendations, helping global manufacturers minimize unplanned downtime and transition from reactive to proactive maintenance.

Virtue AI specializes in AI security and compliance, offering a decentralized, open platform designed for the public good. Their platform provides comprehensive risk assessments for AI applications, ensuring regulatory compliance, and features AI Safety leaderboards for performance benchmarking.

Virtue AI specializes in AI security and compliance, offering a decentralized, open platform designed for the public good. Their platform provides comprehensive risk assessments for AI applications, ensuring regulatory compliance, and features AI Safety leaderboards for performance benchmarking.

Atsena Therapeutics is a clinical-stage company focused on developing gene therapies for inherited retinal diseases. Utilizing an adeno-associated virus (AAV) platform, including a novel spreading capsid, Atsena's clinical programs aim to prevent blindness caused by genetic mutations.

MicroTransponder is a medical device company that develops and commercializes implantable neurostimulation platforms aimed at treating neurological conditions. The company focuses on vagus nerve stimulation to promote neuroplasticity and functional recovery, with products including the Serenity System for tinnitus and Vivistim, an FDA-approved therapy for ischemic stroke survivors with moderate to severe upper-limb impairment more than six months post-stroke. Founded in 2007 and headquartered in Austin, Texas, MicroTransponder's technology combines paired vagus nerve stimulation with wireless delivery of targeted electrical impulses to enhance recovery after neurological injury and disease.

Overland AI develops artificial intelligence-based autonomous navigation systems for off-road vehicles. Its modular software uses machine learning and robotic technologies, enabling autonomous operation in challenging terrains like mines, construction sites, and disaster zones, primarily serving defense and national security sectors.

VeraDermics is a dermatology company specializing in novel drug delivery mechanisms. It offers a dissolvable microneedle patch for treating skin conditions like warts, administering immunotherapy painlessly by stimulating the body's immune system.

Xscape Photonics specializes in developing photonic chips that enhance high-speed connections within data centers and high-performance computing systems. By harnessing photonics technology, the company offers scalable, energy-efficient solutions designed to facilitate advancements in AI, machine learning, and simulation hardware.

Founded in 2015 by Dr. Robert Schoelkopf, Quantum Circuits develops and manufactures quantum computers based on superconducting devices. The company focuses on creating full-stack quantum computers designed for efficient scaling, with a pioneering approach to error detection and correction.

Q32 Bio is a clinical-stage biotechnology company focused on restoring healthy immune balance in autoimmune and inflammatory diseases by developing antibody-based therapies that modulate regulators of the innate and adaptive immune systems. Its development program includes ADX-914, a human anti-IL-7R antibody aimed at rebalancing adaptive immune function, and ADX-097, which demonstrates tissue-targeted distribution and durable pharmacokinetics/pharmacodynamics. Founded in 2017 and based in Cambridge, Massachusetts, the company emphasizes a team of scientists and immunology experts pursuing novel biologics to address diseases with limited or inadequate treatment options.

Quintessent Inc., incorporated in 2019 and headquartered in Santa Barbara, California, is a technology company focused on the commercialization of quantum dot-based lasers and photonic integrated circuits. The company develops advanced optical connectivity solutions that utilize the unique properties of quantum dot gain media, combined with co-designed architectures. This innovation enables high-bandwidth communication channels essential for optical networking, large-scale computing systems, and deep learning applications. By leveraging advanced semiconductor materials and laser architectures, Quintessent aims to facilitate the growth of next-generation optical networks and enhance capabilities in sensing and deep learning systems.

Nocion Therapeutics is a biopharmaceutical company developing novel therapies called 'nocions' that selectively target actively firing nociceptors to provide relief for serious conditions such as cough, itch, pain, and inflammation.

AssetWatch specializes in proactive predictive maintenance solutions. It offers a rapidly deployable remote condition monitoring service featuring wireless sensors, communication hubs, advanced software, and expert analysis. The company combines predictive analytics with expert insights to provide actionable recommendations, helping global manufacturers minimize unplanned downtime and transition from reactive to proactive maintenance.

BioAge Labs develops medicines to treat aging and age-related diseases using its proprietary BioAge platform, which combines systems biology and AI. Its pipeline includes BGE-117 for multiple aging-related conditions, BGE-175 for immune aging and respiratory infections, and azelaprag for obesity in the elderly.

Verve Motion specializes in the development of exo-suits designed to assist workers engaged in physically demanding tasks. By integrating advancements in robotics, apparel design, and movement science, the company creates lightweight wearable technology made from flexible textile materials. These exo-suits are designed to adapt to the natural movements of the wearer, delivering support and force at critical moments while maintaining a nonrestrictive fit. Verve Motion's innovative approach aims to enhance workplace safety and comfort, ultimately improving the efficiency of workers in various industries.

Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Kate Therapeutics is a biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for genetically defined muscle and heart diseases. It employs innovative technology platforms to enhance tissue-specific delivery and gene regulation, addressing key limitations of existing gene therapies.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Hack The Box Ltd. is a company that operates an online platform focused on enhancing skills in penetration testing and cybersecurity for individuals, organizations, and educational institutions. Founded in 2017 and based in Folkestone, United Kingdom, the platform facilitates both guided and exploratory learning experiences, allowing users to tackle real-world scenarios through various challenges, including capture the flag-style exercises. This approach enables cybersecurity professionals to improve their offensive and defensive capabilities, better preparing them for diverse cyber challenges. By offering tools for skills development and talent assessment, Hack The Box plays a crucial role in advancing cybersecurity readiness in the modern digital landscape.

Opsys Technology Co., Ltd. specializes in designing and developing optical communication products, focusing on solutions that utilize advanced fiber optics technologies. The company's product offerings include LIDAR systems, RF over fiber links for various applications such as remote antenna and distributed antenna systems, as well as mixed signal solutions for aircraft and maritime environments. Opsys Tech is also active in sectors requiring temperature and strain sensors, as well as data center switching technologies. With a strong emphasis on autonomous vehicle control and intelligent sensors, the company is committed to innovating new applications within the optical market. Founded as a spinoff from a leading optical communication firm, Opsys Tech is based in Holon, Israel, and continues to expand its portfolio to meet the demands of modern technological advancements.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

Normunity is a biotechnology company that develops precision immuno‑oncology medicines, termed immune normalizers, designed to restore the body’s natural immune response against cancer. Leveraging a partnership with Dr. Lieping Chen’s laboratory at Yale School of Medicine, the company focuses on newly discovered mechanisms of immune disruption, such as the exclusion of T‑cells from immune‑sensitive tumors and other barriers to normal immune function. Its pipeline includes programs targeting these mechanisms to enable clinicians to treat cancer by reactivating the patient’s own immunity. Normunity operates from offices in Boston, Massachusetts, and West Haven, Connecticut.

Founded in 2016, Metalenz specializes in the research, development, and production of innovative optical components. Utilizing metasurface technology, it creates ultra-thin planar optics for high-resolution imaging, enabling miniaturization and weight reduction in mobile phones, computers, and other electronic devices.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.

AssetWatch specializes in proactive predictive maintenance solutions. It offers a rapidly deployable remote condition monitoring service featuring wireless sensors, communication hubs, advanced software, and expert analysis. The company combines predictive analytics with expert insights to provide actionable recommendations, helping global manufacturers minimize unplanned downtime and transition from reactive to proactive maintenance.

MicroTransponder is a medical device company that develops and commercializes implantable neurostimulation platforms aimed at treating neurological conditions. The company focuses on vagus nerve stimulation to promote neuroplasticity and functional recovery, with products including the Serenity System for tinnitus and Vivistim, an FDA-approved therapy for ischemic stroke survivors with moderate to severe upper-limb impairment more than six months post-stroke. Founded in 2007 and headquartered in Austin, Texas, MicroTransponder's technology combines paired vagus nerve stimulation with wireless delivery of targeted electrical impulses to enhance recovery after neurological injury and disease.

Brimstone develops a carbon-negative process for producing ordinary portland cement and supplementary cementitious material. Its technology uses calcium silicate rock instead of limestone, delivering identical products at scale while significantly reducing CO2 emissions.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Vanqua Bio is a biotechnology company dedicated to discovering and developing innovative medicines for patients with neurodegenerative diseases. The company's proprietary platform employs human genetics and patient-derived neuronal cells to identify and validate novel disease pathways related to lysosomal dysfunction or aberrant immune system activation, aiming to translate these findings into clinically effective treatments.

Corelight, Inc. is a provider of network visibility solutions aimed at enhancing cybersecurity for enterprises, government entities, and educational institutions. Founded in 2013 and headquartered in San Francisco, California, the company develops a suite of products that includes Corelight sensors and a fleet management system. Its flagship offering is based on Bro, an open-source network analysis framework that delivers actionable, real-time data, enabling security professionals to comprehensively understand network traffic and effectively detect and mitigate cyber threats. In addition to its headquarters, Corelight maintains offices in Santa Clara, California, and Columbus, Ohio, further supporting its commitment to improving network security across various sectors.

eFFECTOR Therapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, California, that specializes in the development of selective translation regulators for the treatment of cancer and other serious diseases. Founded in 2012, the company is pioneering a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). These drug candidates specifically target the eIF4F complex and its associated kinase, MNK 1/2, which play critical roles in protein synthesis and are linked to prominent cancer signaling pathways such as PI3K-AKT and RAS-MEK. eFFECTOR's products aim to inhibit pathways that drive tumor growth, survival, and immune evasion by regulating the expression of oncoproteins and immunosuppressive proteins. The lead candidate, tomivosertib, is currently being evaluated in a Phase 2b trial for non-small cell lung cancer in combination with pembrolizumab. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation in a Phase 1/2 trial, with further expansion cohorts anticipated. The company also collaborates with Pfizer to advance inhibitors targeting eIF4E.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Sonoma Biotherapeutics, Inc. is focused on developing adoptive T regulatory (Treg) cell therapies aimed at treating autoimmune and degenerative diseases. Established in 2019 and based in South San Francisco, California, with an additional office in Seattle, the company employs next-generation genome editing and target-specific cell therapy techniques to innovate in the field of Treg cell therapeutics. The firm aims to create disease-modifying and potentially curative therapies that promote self-tolerance and inhibit harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded by experts in Treg biology and cell therapy, Sonoma Biotherapeutics integrates advanced methodologies to enhance its therapeutic offerings.

Verve Motion specializes in the development of exo-suits designed to assist workers engaged in physically demanding tasks. By integrating advancements in robotics, apparel design, and movement science, the company creates lightweight wearable technology made from flexible textile materials. These exo-suits are designed to adapt to the natural movements of the wearer, delivering support and force at critical moments while maintaining a nonrestrictive fit. Verve Motion's innovative approach aims to enhance workplace safety and comfort, ultimately improving the efficiency of workers in various industries.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.

Hack The Box Ltd. is a company that operates an online platform focused on enhancing skills in penetration testing and cybersecurity for individuals, organizations, and educational institutions. Founded in 2017 and based in Folkestone, United Kingdom, the platform facilitates both guided and exploratory learning experiences, allowing users to tackle real-world scenarios through various challenges, including capture the flag-style exercises. This approach enables cybersecurity professionals to improve their offensive and defensive capabilities, better preparing them for diverse cyber challenges. By offering tools for skills development and talent assessment, Hack The Box plays a crucial role in advancing cybersecurity readiness in the modern digital landscape.

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology. The firm is focused on developing innovative antibody-drug conjugate therapies targeting CD46, aimed at treating late-stage multiple myeloma and prostate cancer, among other indications. Utilizing its platform, Fortis Therapeutics prepares antibody-drug conjugates that are designed to effectively address both adenocarcinoma and neuroendocrine cancers, providing oncologists with new therapeutic options for challenging late-stage malignancies.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Artizan Biosciences, Inc. is a biotechnology company focused on developing small molecule drugs for human use, particularly targeting diseases linked to intestinal inflammation. Founded in 2016 and headquartered in New Haven, Connecticut, the company employs its proprietary IgA-SEQ technology platform to identify and characterize disease-driving bacteria within the intestinal microbiota. This innovative approach aims to create precision therapeutics that address the root causes of various serious conditions, including digestive disorders, obesity, autoimmune diseases, and a range of other health issues affecting the skin, lungs, and central nervous system. By focusing on unmet medical needs, Artizan Biosciences seeks to provide novel treatment options for patients.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Neuros Medical, Inc. is a neuromodulation company dedicated to developing innovative therapies to address unmet medical needs for patients globally. Founded in 2008 and headquartered in Willoughby Hills, Ohio, the company specializes in its proprietary platform technology known as Electrical Nerve Block. This technology is designed to eliminate chronic pain across various conditions, including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine. The Neuros Altius System, one of its key products, includes an implantable generator with an integrated rechargeable battery, a cuff electrode, and external devices, further demonstrating the company's commitment to advancing pain management solutions.

Coho Therapeutics, Inc. is a biotechnology company founded in 2019 and headquartered in San Diego, California. The company specializes in developing molecular glue therapeutics aimed at degrading proteins associated with cancer, neurodegeneration, and other serious diseases. By focusing on this innovative approach, Coho Therapeutics seeks to create new classes of medicines that enable healthcare professionals to prevent and treat various lethal conditions.

Atsena Therapeutics is a clinical-stage company focused on developing gene therapies for inherited retinal diseases. Utilizing an adeno-associated virus (AAV) platform, including a novel spreading capsid, Atsena's clinical programs aim to prevent blindness caused by genetic mutations.

Menlo Security is a cybersecurity company headquartered in Mountain View, California, founded in 2012. It offers a cloud‑based isolation platform that protects organizations from malware by executing all web content, documents, and email attachments in a remote sandbox. Users can safely interact with websites and files without exposing their local environment to malicious code. The platform serves Fortune 500 companies and financial services institutions worldwide, with operations across North America, EMEA, APAC, and other regions.

Q32 Bio is a clinical-stage biotechnology company focused on restoring healthy immune balance in autoimmune and inflammatory diseases by developing antibody-based therapies that modulate regulators of the innate and adaptive immune systems. Its development program includes ADX-914, a human anti-IL-7R antibody aimed at rebalancing adaptive immune function, and ADX-097, which demonstrates tissue-targeted distribution and durable pharmacokinetics/pharmacodynamics. Founded in 2017 and based in Cambridge, Massachusetts, the company emphasizes a team of scientists and immunology experts pursuing novel biologics to address diseases with limited or inadequate treatment options.

Palladio Biosciences, Inc. is a biotechnology company focused on developing innovative medicines for orphan kidney diseases. Established in 2015 and headquartered in Horsham, Pennsylvania, the company is primarily engaged in creating therapeutics for conditions such as polycystic kidney disease (PKD), a serious genetic disorder characterized by the formation of fluid-filled cysts in the kidneys. One of its key products, Lixivaptan, is a selective vasopressin V2 receptor antagonist aimed at treating PKD, helping to prevent disease progression and improve patient outcomes. Palladio Biosciences is dedicated to addressing unmet medical needs in the field of renal diseases.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

ESCAPE Bio is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for genetically defined subpopulations affected by neurodegenerative diseases. Founded in 2015 and based in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and sphingolipid storage disorders. ESCAPE Bio's pipeline includes innovative candidates like ESB1609, a small molecule S1P5 receptor agonist targeting CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor specifically designed for Parkinson's patients with the LRRK2 G2019S variant. Additionally, the company is developing a program aimed at addressing the needs of Alzheimer's patients who carry the ApoE4 risk allele. Through its precision-targeted approach, ESCAPE Bio seeks to provide effective treatment options for individuals with these complex genetic profiles.

Nido Biosciences is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing precision medicines and small-molecule therapeutics for severe neurological and neuromuscular diseases. It employs a functional genomics platform using human cell lines and tailored screens to identify therapeutic targets driven by human genetics, with the aim of addressing the underlying biology of disease and restoring healthy cell function through targeted interventions.

SiFive, Inc. is a semiconductor company that specializes in designing and manufacturing chips, particularly focusing on RISC-V architecture. Established in 2015 and headquartered in San Mateo, California, with additional offices in locations such as Oregon, Texas, India, Taiwan, and France, SiFive provides a range of products including multi-core application processors, embedded microcontrollers, and system-on-chip solutions tailored for various applications such as IoT and wearables. The company emphasizes the use of open-source technology to enable faster and more cost-effective hardware development. By offering software development kits, toolchains, and customized silicon products, SiFive aims to democratize access to advanced semiconductor solutions, accelerating innovation for businesses of all sizes.

Aerovate Therapeutics, founded in 2018 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to improving the lives of patients with rare cardiopulmonary diseases. Its primary focus is AV-101, an inhaled dry powder formulation of imatinib, designed to deliver medication directly to affected lung tissues while minimizing systemic side effects. This innovative approach aims to treat pulmonary arterial hypertension (PAH), a severe and progressive disease.

Founded in 2017, Censys offers an internet intelligence platform that provides real-time visibility into global networks and devices. Its solution enables businesses to discover unknown assets, monitor remote workforce, identify threat actors, and manage attack surfaces proactively.

Vor Biopharma develops innovative cancer therapies focused on engineered hematopoietic stem cells (eHSCs). Its lead product candidate, VOR33, is designed to treat acute myeloid leukemia by generating healthy cells resistant to targeted immunotherapies. Incorporated in 2015, the company is based in Cambridge, Massachusetts.

StreetLight Data, Inc. is a technology company specializing in cloud-based analytics solutions that focus on transportation measurement and management for both public and private sectors. Its primary product, StreetLight InSight, is an online platform that analyzes mobility patterns using Big Data by converting anonymous location data from mobile devices into actionable insights. This platform allows users, including transportation engineers and urban planners, to assess mobility across various roads and zones, thereby facilitating informed infrastructure deployment and transportation planning. Additionally, StreetLight Data offers RouteScience, which organizes disparate location data into coherent travel patterns. Founded in 2012 and headquartered in San Francisco, California, the company also has offices in Richmond, Virginia, and Vancouver, Canada, and is dedicated to enhancing smart city initiatives through improved understanding of transportation behaviors.

Atsena Therapeutics is a clinical-stage company focused on developing gene therapies for inherited retinal diseases. Utilizing an adeno-associated virus (AAV) platform, including a novel spreading capsid, Atsena's clinical programs aim to prevent blindness caused by genetic mutations.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule therapies targeting p53 mutations in cancer. Its lead candidate, PC14586, aims to correct and restore the function of the p53 protein, which is critical in regulating cell growth and preventing tumor formation. In addition to PC14586, the company is developing therapies for various p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals leverages extensive expertise in p53 biology to advance its innovative treatment options for cancer patients.

IonQ is a quantum computing company that develops general-purpose quantum information processors based on trapped-ion technology. Its approach enables qubit replication, optical networkability, and optimized algorithms to support scalable quantum computation beyond classical capabilities. Founded in 2015 and based in College Park, Maryland, IonQ offers access to its quantum computers through cloud platforms, providing quantum-computing-as-a-service to a broad user base and select customers through its own cloud service. Revenue streams include QCaaS arrangements and related consulting and co-development contracts for algorithm design and system integration.

ArsenalBio is a programmable cell therapy company established in 2019, focused on developing and commercializing innovative immune cell therapies, particularly for cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create multifunctional T-cell therapies. ArsenalBio's approach involves the precise insertion of large synthetic DNA sequences, enabling the generation of next-generation autologous T-cell therapies. By integrating these cutting-edge methods, ArsenalBio aims to enhance the effectiveness and safety of immune cell therapies, reduce costs for healthcare providers, and improve market access, ultimately broadening patient outcomes and making these therapies more widely available.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company based in Blacksburg, Virginia, focused on developing innovative oral therapeutics for autoimmune diseases, particularly inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. Founded in 2017, the company aims to address unmet medical needs through its unique approach to treatment, leveraging novel mechanisms of action. Its lead product candidate, NX-13, is a gut-selective NLRX1 agonist designed to modulate immune responses, and it is part of a broader pipeline that includes other internally discovered compounds targeting various pathways at the intersection of immunity and metabolism. Landos Biopharma's commitment to developing first-in-class therapeutics underscores its dedication to improving patient outcomes in the field of autoimmune disorders.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

Menlo Security is a cybersecurity company headquartered in Mountain View, California, founded in 2012. It offers a cloud‑based isolation platform that protects organizations from malware by executing all web content, documents, and email attachments in a remote sandbox. Users can safely interact with websites and files without exposing their local environment to malicious code. The platform serves Fortune 500 companies and financial services institutions worldwide, with operations across North America, EMEA, APAC, and other regions.

Artizan Biosciences, Inc. is a biotechnology company focused on developing small molecule drugs for human use, particularly targeting diseases linked to intestinal inflammation. Founded in 2016 and headquartered in New Haven, Connecticut, the company employs its proprietary IgA-SEQ technology platform to identify and characterize disease-driving bacteria within the intestinal microbiota. This innovative approach aims to create precision therapeutics that address the root causes of various serious conditions, including digestive disorders, obesity, autoimmune diseases, and a range of other health issues affecting the skin, lungs, and central nervous system. By focusing on unmet medical needs, Artizan Biosciences seeks to provide novel treatment options for patients.

SiFive, Inc. is a semiconductor company that specializes in designing and manufacturing chips, particularly focusing on RISC-V architecture. Established in 2015 and headquartered in San Mateo, California, with additional offices in locations such as Oregon, Texas, India, Taiwan, and France, SiFive provides a range of products including multi-core application processors, embedded microcontrollers, and system-on-chip solutions tailored for various applications such as IoT and wearables. The company emphasizes the use of open-source technology to enable faster and more cost-effective hardware development. By offering software development kits, toolchains, and customized silicon products, SiFive aims to democratize access to advanced semiconductor solutions, accelerating innovation for businesses of all sizes.

Founded in 2013, Algorithmia provides a platform for deploying and managing machine learning models at scale. It enables algorithm developers to explore, create, and share algorithms as Web services, supporting popular frameworks like TensorFlow, PyTorch, and Scikit-learn. The company automates MLOps, empowering data scientists and developers while powering mission-critical workloads for its enterprise customers.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, focused on developing a community-owned platform for health and DNA research. The company's primary offering is LunaDNA, a genomic and medical research knowledge database that enables individuals to share their health and DNA data for research purposes. This platform facilitates collaborations with pharmaceutical companies, insurance providers, and healthcare IT organizations to drive advancements in medical discoveries. By allowing members to contribute their health data, LunaPBC not only supports vital health research projects but also ensures that participants can share in the financial benefits arising from medical breakthroughs, fostering a sense of community ownership and engagement in the research process.

LunaDNA is a community-owned genomic and medical research platform founded by the creators of a leading DNA sequencing company. It facilitates the sharing of health and DNA data, allowing individuals to contribute their personal information for medical research while maintaining ownership of their data. By incentivizing participation, LunaDNA addresses the challenge of data silos that have emerged as personal DNA sequencing has gained popularity. Participants are rewarded with shares in the database, granting them a stake in the profits generated from medical research. These profits are returned to the community as dividends when researchers pay for access to the data. LunaDNA empowers individuals to support health research while ensuring that their contributions benefit the broader community and drive medical discoveries.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that incorporates a proprietary dry-powder formulation of dihydroergotamine mesylate. Designed for self-administration, STS101 utilizes a pre-filled, single-use nasal delivery device, enhancing patient convenience and accessibility. The product is currently undergoing Phase III clinical trials, marking a significant step in its development. Founded in 2016, Satsuma is headquartered in South San Francisco, California.

Arrakis Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, that specializes in drug discovery focused on ribonucleic acid (RNA) targets. Established in 2015, the company utilizes a proprietary platform that combines advanced RNA bioinformatics, structural tools, and chemical libraries to identify new RNA targets and develop RNA-targeted small molecules (rSMs). This innovative approach aims to address various diseases, including cancer, neurological disorders, and rare genetic conditions. Arrakis also offers SHAPEware, a software tool designed to analyze and predict RNA secondary structures and potential ligand-binding sites, further enhancing its drug development capabilities. Through its comprehensive pipeline, Arrakis Therapeutics seeks to improve treatment options and outcomes for patients across multiple therapeutic areas.

Hyalex Orthopaedics, Inc. is a medical device company based in Lexington, Massachusetts, focused on developing and commercializing innovative products utilizing its proprietary HYALEX technology. This synthetic polymer is specifically designed to mimic the properties of natural cartilage, offering a unique advantage in maintaining low friction and wear under the high loads typically encountered in human joints. The company's goal is to provide solutions for diseased and damaged joints by enabling the replacement of arthritic cartilage while preserving healthy bone. Currently, Hyalex Orthopaedics' products remain in the development stage and have yet to receive regulatory approval for human use.

Vor Biopharma develops innovative cancer therapies focused on engineered hematopoietic stem cells (eHSCs). Its lead product candidate, VOR33, is designed to treat acute myeloid leukemia by generating healthy cells resistant to targeted immunotherapies. Incorporated in 2015, the company is based in Cambridge, Massachusetts.

KenSci Inc. is a healthcare technology company that specializes in developing a machine learning platform aimed at improving risk prediction for healthcare providers and payers. Founded in 2015 and headquartered in Seattle, Washington, with additional offices in Hyderabad and Singapore, KenSci's platform integrates and analyzes data from various sources, including clinical records, claims, and patient-generated information. This enables healthcare organizations to identify clinical, financial, and operational risks, allowing for earlier interventions that can save costs and improve patient outcomes. The platform offers a library of pre-built models and modular solutions, facilitating seamless integration into existing workflows to enhance hospital operations and care coordination. By leveraging Explainable AI, KenSci ensures that its risk-based predictions are both efficient and accountable, ultimately supporting the delivery of better healthcare.

Seismos is a data analytics company specializing in production optimization through proprietary solutions that enable real-time monitoring of underground fluid flow within reservoirs during production. Unlike conventional seismic technologies, which require months for data acquisition and processing, disrupt production, and incur high costs, Seismos offers a more efficient alternative. The company's cloud-based K-wave technology provides real-time information non-invasively, significantly reducing expenses. Additionally, Seismos develops AI-powered sensing systems that utilize non-invasive acoustic sensing and machine learning to detect and predict anomalies in various markets, including upstream, pipelines, and geothermal sectors. This allows organizations to take immediate data-driven actions.

Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Elementary Robotics, Inc. is a Pasadena, California-based company that specializes in the manufacture of robots designed to assist humans in various industrial applications. Founded in 2017, Elementary Robotics focuses on automating quality assurance and traceability processes within AI-assisted manufacturing. Their robots are utilized to monitor and track the stages of assembly along production lines, serving diverse sectors such as electronics, automotive, medical, consumer packaged goods, and logistics. The company combines hardware and software to create a robust platform that leverages machine learning and computer vision, enabling intelligent automation of workflows. By providing easy-to-use software and deep learning AI, Elementary Robotics aims to enhance efficiency and productivity in repetitive tasks across various industries.

Vector Launch, Inc. is a company based in Tucson, Arizona, that specializes in developing software and launch vehicles tailored for micro and nano satellites. Founded in 2016 by several former members of the original SpaceX team, the company aims to provide affordable and frequent access to space, thereby facilitating innovation for startups in the aerospace sector. Vector Launch operates a vehicle and propulsion engineering facility, with additional offices located in Long Beach and San Jose, California. The company's approach combines low-cost dedicated launches with software-defined satellites, enhancing the speed and accessibility of satellite deployment. Vector Launch's offerings are particularly valuable for micro satellite developers, national security applications, and other government entities, helping to lower the barriers to entry for innovation and commerce in outer space. However, in December 2019, the company filed for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Modis Therapeutics, Inc. is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases characterized by high unmet medical needs. Incorporated in 2016 and based in Oakland, California, the company is known for its lead therapy, MT1621, which aims to restore mitochondrial DNA replication fidelity. This therapy specifically targets thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disorder. By improving nucleotide balance and increasing mitochondrial DNA copy number, Modis Therapeutics' approach seeks to enhance cellular function and prolong the lives of affected patients. As of September 2019, Modis Therapeutics operates as a subsidiary of Zogenix, Inc.

MC10, Inc. is a company that specializes in developing wearable medical sensors designed to collect clinical-grade biometric and physiological data. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of innovative products, including BioStamp nPoint for vital signs and activity monitoring, Kintinuum for orthopedic rehabilitation, WiSP for cardiac monitoring, and BioStampMD, a conformal sensor that gathers both objective and subjective health data. MC10 employs advanced flexible electronics technology, allowing its devices to bend and stretch with the body, ensuring comfort and ease of use. The company focuses on enhancing human capabilities and improving health insights through discreet, location-specific sensing that captures real-world data on muscle activation and movement, with applications extending across various sectors including sports, military, and energy.

Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on creating distinct and transformative therapies that address significant unmet medical needs in this area. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing clinical care and improving the quality of life for patients, families, and caregivers.

Infinite Uptime provides an IoT-based predictive maintenance platform for industrial machinery, combining hardware, cloud analytics, and control software to monitor equipment, diagnose problems, and guide maintenance decisions. Its platform includes an industrial data analytics capability that detects patterns, measures overall equipment effectiveness, tracks productivity trends, and supports ISO compliance across multiple tools on a single machine. The company also offers sensors and visual indicators for real-time anomaly detection, enabling proactive maintenance in demanding environments. Serving industries such as steel, power, cement, chemicals, automotive, and textiles, Infinite Uptime targets global manufacturing operations to reduce downtime and improve plant performance. Founded in 2015 and based in Berkeley, California, with development and manufacturing activities in India, the company integrates hardware, software, and analytics to optimize asset reliability.

StreetLight Data, Inc. is a technology company specializing in cloud-based analytics solutions that focus on transportation measurement and management for both public and private sectors. Its primary product, StreetLight InSight, is an online platform that analyzes mobility patterns using Big Data by converting anonymous location data from mobile devices into actionable insights. This platform allows users, including transportation engineers and urban planners, to assess mobility across various roads and zones, thereby facilitating informed infrastructure deployment and transportation planning. Additionally, StreetLight Data offers RouteScience, which organizes disparate location data into coherent travel patterns. Founded in 2012 and headquartered in San Francisco, California, the company also has offices in Richmond, Virginia, and Vancouver, Canada, and is dedicated to enhancing smart city initiatives through improved understanding of transportation behaviors.

Spero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for multi-drug resistant bacterial infections and rare diseases. Its primary focus is on tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adult use in treating MDR Gram-negative infections.

Seismos is a data analytics company specializing in production optimization through proprietary solutions that enable real-time monitoring of underground fluid flow within reservoirs during production. Unlike conventional seismic technologies, which require months for data acquisition and processing, disrupt production, and incur high costs, Seismos offers a more efficient alternative. The company's cloud-based K-wave technology provides real-time information non-invasively, significantly reducing expenses. Additionally, Seismos develops AI-powered sensing systems that utilize non-invasive acoustic sensing and machine learning to detect and predict anomalies in various markets, including upstream, pipelines, and geothermal sectors. This allows organizations to take immediate data-driven actions.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

Embodied, Inc. is a robotics company based in Pasadena, California, specializing in the development of personal companion robots aimed at enhancing care and wellness. Founded in 2016 and formerly known as CareBots, Inc., the company has created Moxie, an interactive robot designed for children that promotes social, emotional, and cognitive development through play-based learning. Drawing on over 14 years of research in socially assistive robotics from the University of Southern California and extensive experience in consumer robotics, Embodied combines advanced artificial intelligence with engaging storytelling and animation techniques. The company's mission is to improve the quality of life for individuals and families by providing life-like, interactive robots that serve as motivators, coaches, and companions, empowering users to improve their own well-being.

Iconic Therapeutics, Inc. is a biopharmaceutical company based in South San Francisco, California, that focuses on developing innovative therapeutics targeting retinal diseases and cancer through the biology of tissue factor. The company has an exclusive license for a novel recombinant protein known as hI-con1, which functions as an immunoconjugate that activates the immune system to eliminate pathological cells, such as those involved in wet age-related macular degeneration and certain cancers. hI-con1 binds to tissue factor, prompting natural killer cells to destroy aberrant neovascular blood vessels and potentially disrupting the feedback loop with vascular endothelial growth factor (VEGF), thus reducing its levels. Phase 1 studies of hI-con1 have shown promising results, demonstrating biological activity without dose-limiting toxicities. Iconic Therapeutics aims to translate scientific insights into effective treatments for serious diseases by addressing the underlying causes of inflammation and angiogenesis.

Precision BioSciences, founded in 2006, is a biotechnology company headquartered in Durham, North Carolina. It specializes in genome editing, developing therapeutic products using its proprietary ARCUS technology. The company focuses on creating allogeneic CAR T immunotherapies to treat cancers like acute lymphoblastic leukemia and non-hodgkin lymphoma, as well as genetic disorders.

Ambiq Micro, Inc. is a fabless semiconductor company based in Austin, Texas, specializing in the development of ultra-low power integrated circuits tailored for power-sensitive applications. Founded in 2010, the company utilizes innovative subthreshold power optimized technology to create real-time clock and microcontroller products designed for wearables, smart cards, wireless sensors, and Internet-of-Things devices. By focusing on ultra-low-power mixed-signal solutions, Ambiq Micro aims to enhance the efficiency of wireless electronics, facilitating the creation of devices that either minimize or eliminate battery use while maximizing design flexibility. The company also provides technical support services and operates additional offices in San Jose, California, as well as in Shanghai, Shenzhen, and Taiwan.

Medisix Therapeutics, established in 2016 and headquartered in Singapore, is an early-stage biotechnology company specializing in cell therapy. It focuses on developing chimeric antigen receptor (CAR) T-cell therapies to target and treat T-cell lymphomas and leukemias. The company's technology platform is built upon the pioneering work of Professor Dario Campana, MD, PhD, a renowned expert in translational immunology and the founder of CAR-T cell biology. Medisix's proprietary immune engineering approaches enable the targeting of T cell leukemias and lymphomas using cell therapy.

Beam Therapeutics is a biotechnology company developing precision genetic medicines using its proprietary base editing technology. Its focus includes therapies for hematological and genetic diseases, with ongoing programs targeting sickle cell disease, alpha-1 antitrypsin deficiency, and other serious conditions.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

Synthorx, Inc. is a biopharmaceutical company specializing in the development of innovative protein therapeutics using advanced synthetic biology techniques. Founded in 2014 and headquartered in La Jolla, California, Synthorx focuses on its proprietary Synthorin programs aimed at treating cancer and autoimmune disorders. Its lead product candidate, THOR-707, is a modified form of recombinant human IL-2, currently being evaluated for various solid tumors both as a standalone treatment and in combination with immune checkpoint inhibitors. The company also develops Synthorins targeting IL-2 for autoimmune conditions, IL-10 for immuno-oncology applications, and IL-15 for regulating immune responses. Synthorx leverages a unique platform that enables the incorporation of synthetic DNA base pairs to enhance the specificity and efficacy of its protein therapeutics, thus offering improved treatment options for patients. Previously known as Alinos, Inc., the company acquired exclusive rights to its synthetic biology technology based on groundbreaking research from The Scripps Research Institute. As of January 2020, Synthorx operates as a subsidiary of Sanofi.